ATLANTA, GA--(Marketwired - Nov 11, 2015) - Medovex Corp. (
Under the terms of the agreement, Dr. Kapoor will leverage his expertise, experience and relationships in the spine surgical treatment space, specifically the Facet Joint pain area. Dr. Kapoor will also provide services to help introduce the Medovex's DenerveX™ System to other leading physicians and medical professionals throughout Europe.
Dr. Kapoor is a consultant orthopedic surgeon with sub specialist expertise in spinal surgery, where his care utilizes modern non-operative and operative techniques. His areas of expertise and interest are minimally invasive (small incision) spinal surgery such as microdiscectomy, X-Stop surgery for spinal stenosis, cement augmentation of painful spinal fractures and back pain treatments.
The majority of Dr. Kapoor's surgical training was on the south coast of England with senior registrar training in Southampton University Hospital.
Dr. Kapoor spent the first four years of the training program covering all aspects of orthopedic and trauma surgery, and dedicated the last three years entirely too spinal surgery. His expertise in spinal surgery was attained from holding the national spinal fellowship post at the Leeds spinal unit, an internationally renowned spinal unit, under the supervision of Professor Bob Dickson, Dr. Peter Millner (St. James Hospital, Orthopedic Spinal Surgery) and Dr. Jerry Towns at Leeds General Infirmary (Neurosurgery). He is actively involved in teaching and research.
Patrick Kullmann, Medovex President and COO stated, "We look forward to working with Dr. Kapoor, leveraging both his expertise and relationships as one of UK's top spine surgeons. We expect his deep knowledge of the space will prove invaluable for our European launch preparation of the DenerveX System."
The DenerveX System is designed to provide relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.
The DenerveX System consists of the DenerveX device, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system. The Company's patented DenerveX System, currently in development and not yet FDA cleared, CE marked or commercially available.
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward- looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.